Olivia Vergnolle, PhD, is a Lead Drug Development in the MSK Therapeutics Bridge Labs (TxBL) program, in the Office of Entrepreneurship & Commercialization (OEC). Her responsibilities include protein engineering and bioanalytical characterization of therapeutic antibody and protein candidates for developability testing and manufacturability assessment. This later step ensures a seamless transition of projects from the discovery to development phase, and ultimately advancement to clinical trials.
Prior joining MSK, she worked at the Sanders Tri-Institutional Therapeutics Discovery Institute. Olivia obtained her PhD in Biochemistry from Cambridge University; she later undertook postdoctoral studies at Weill Cornell Medicine and the City University of New York, and then obtained an appointment as a Research Assistant Professor at the Albert Einstein College of Medicine, where she developed immunogen- and antibody-based antiviral treatments.